Benitec Biopharma (NASDAQ:BNTC) Upgraded at Wedbush

Posted by Brian Himes on Jul 29th, 2026

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) was upgraded by investment analysts at Wedbush to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Guggenheim downgraded shares of Benitec Biopharma from a “buy” rating to a “neutral” rating in a research note on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Benitec Biopharma in a report on Friday, July 17th. Finally, Evercore began coverage on Benitec Biopharma in a research note on Tuesday, May 12th. They issued an “outperform” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Benitec Biopharma has a consensus rating of “Moderate Buy” and an average price target of $24.80.

Read Our Latest Research Report on Benitec Biopharma

Benitec Biopharma Stock Performance

BNTC stock opened at $11.89 on Tuesday. The company’s 50 day moving average price is $11.99 and its 200 day moving average price is $11.81. The firm has a market capitalization of $408.42 million, a price-to-earnings ratio of -10.43 and a beta of 0.25. Benitec Biopharma has a fifty-two week low of $9.85 and a fifty-two week high of $16.76.

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03. Equities analysts forecast that Benitec Biopharma will post -1.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of BNTC. GAMMA Investing LLC boosted its holdings in shares of Benitec Biopharma by 18.7% in the 2nd quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 1,256 shares in the last quarter. Bank of America Corp DE lifted its position in Benitec Biopharma by 43.3% in the first quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock valued at $185,000 after acquiring an additional 5,251 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in Benitec Biopharma in the first quarter valued at $186,000. Bank of New York Mellon Corp boosted its stake in Benitec Biopharma by 37.6% in the first quarter. Bank of New York Mellon Corp now owns 43,489 shares of the biotechnology company’s stock valued at $463,000 after acquiring an additional 11,877 shares in the last quarter. Finally, Simplify Asset Management Inc. grew its holdings in shares of Benitec Biopharma by 271.9% during the first quarter. Simplify Asset Management Inc. now owns 562,242 shares of the biotechnology company’s stock worth $5,988,000 after purchasing an additional 411,079 shares during the last quarter. Institutional investors and hedge funds own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

(Get Free Report)

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.